Partikula Appoints Leading Cancer Metabolism Experts to Advisory Board; Extends Its Work On Its Multiple Checkpoint Inhibitors; Adds Seasoned Technical Development Professional to the Management Team

The addition of Matthew Vander Heiden, MD, PhD and Joshua Rabinowitz, MD, PhD bring world-class cell metabolism expertise to the Partikula Scientific Advisory Board Partikula continues to strengthen its management team as J. Michael Ramstack PhD joins the company as Vice President of Technical Operations October 13, 2016 08:00 AM Eastern Daylight Time SUNRISE, Fla.–(BUSINESS WIRE)–Partikula LLC, a late stage preclinical biotechnology company, today announced the addition of Dr. Matthew Vander Heiden and Dr. Joshua Rabinowitz to the company’s Scientific Advisory Board. “Matt and Josh bring to our team world-class expertise in the areas of cancer and cell metabolism that is second to none. Their scientific and clinical knowledge will compliment the therapeutic development work our scientists have been doing utilizing our mitochondria-targeting chemistries to modulate cancer metabolism and destroy tumors. We are very excited to have them on board and look forward to working together to bring novel and important medicines to patients,” said David Kolb, CEO of Partikula. Dr. Vander Heiden added, “The early results generated by the Partikula team are exciting. Their mitochondria-targeting chemistries seem to have afforded them the opportunity to access some interesting targets which I believe could have significant impact in the development of novel cancer therapies.” Dr. Vander Heiden is an Associate Professor at the Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, as well as an Instructor of Medicine, Dana Farber Cancer Institute and Harvard Medical School. Dr. Vander Heiden is also an Institute Member of Broad Institute of MIT and Harvard. Dr. Vander Heiden is a Member of Scientific Advisory Board at Aeglea Biotherapeutics...